Dark pool activity was detected in PLTR stock on January 3, 2022.
PLTR Dark Pool Trade
Make sure to review this lesson on dark pool trading so that you understand the chart above.
The dark pool print occurred in the after-hours market and so it’s very difficult to determine if the dark pool trade was bullish or bearish. I think we’ll probably know if the trade was a buy order or a sell order over the next few days depending on if the stock goes up or down.
Palantir and Dewpoint Therapeutics Announce Strategic Partnership
On December 20, 2021, Palantir Technologies Inc. (NYSE: PLTR), a leading builder of operating systems for the modern enterprise, and Dewpoint Therapeutics (“Dewpoint”), the leading biomolecular condensates company, announced a partnership for Palantir’s Foundry platform to help power Dewpoint’s efforts to discover treatments and cures for the most challenging diseases.
Palantir Foundry will help to enable researchers at Dewpoint to further their understanding of condensates biology by analyzing lab data along with other data sources, including data from the published literature and databases, to identify new compounds and therapeutic approaches.
Dewpoint will also use Foundry as the primary platform for its centralized knowledge repository, helping it contextualize its experimental results and prioritize the most viable outcomes. This multi-year agreement marks one of Palantir’s most comprehensive partnerships with a biotechnology company.
Palantir Foundry is designed to integrate disparate and siloed information sources to lead to data-driven analysis and decision-making. It allows users to track lineage across systems, making it particularly suited for work in life sciences and the biotechnology sector, where data sources come from several unique and separate systems.
At Dewpoint, Foundry will be able to work seamlessly with the existing systems in its laboratories to provide researchers with a comprehensive foundation for exploration and analysis.
“We think Dewpoint is changing the way the world approaches drug design by exploring new frontiers of disease biology, requiring a game-changing solution that goes beyond just cloud and infrastructure to drive their R&D and scale with their vision as they grow,” said Lalarukh Haris Shaikh, Palantir’s Head of Biotech. “We are proud to partner with Dewpoint and share their passion of working on one of the most exciting translational medicine approaches of our time.”
Foundry will help researchers make decisions around compound and target viability and streamline experiments and automate analysis by creating a digital twin of the research environment. One concrete example of Foundry’s use at Dewpoint Therapeutics is the expansion of the data foundation to include advanced genetic analysis for disease association and correlation with condensate content, empowering future discoveries.
“Key to our approach has been creating a seamless connection between our wet-lab and dry-lab capabilities, with machine learning and AI at the center. Foundry has provided us with a solid foundation for us to fully connect and operationalize our entire lab to enterprise and enable the discovery and development of new drugs,” said Dewpoint CEO Ameet Nathwani.
Army Vantage Reaffirms Palantir Partnership for a Third Consecutive Year With $116M Agreement
On December 17, 2021, Palantir Technologies Inc. (NYSE:PLTR) announced that the U.S. Army’s Program Executive Office for Enterprise Information Systems (PEO EIS) opted to execute the second option year of its partnership with Palantir on the Army Vantage program, for $116.3 million for the year.
Army Vantage is powered by Palantir’s software, which provides a central operating system that enhances readiness and offers near real-time visibility and controlled access to disparate Army data sources on an integrated data platform. The Palantir platform enables organizations to make better use of the data they have by breaking down silos and offering a single operating picture for decision making.
In December 2019, the U.S. Army selected Palantir for a $458 million production agreement to power Army Vantage, a comprehensive data analytics platform to facilitate data-driven decision-making. The contract was for a base year and three option years. Palantir was awarded $110 million at the time for the base year, and $113.8 million in December 2020 for the first option year.
The Army Vantage platform was established to enable users to make data-driven decisions, allowing the Army to leverage its data as a strategic asset. Palantir’s continued partnership with the Army since the platform’s launch has helped generate and integrate over 30,000 unique data sets from over 160 distinct systems.
Over the last year, Army Vantage implemented an application to help command teams plan, avoid, and manage Soldiers’ risk behaviors, provided leaders with visibility into the Army’s COVID-19 inventory and Soldier immunization rates, and helped improve the Army’s process for weapons accountability. In May, Army Vantage received an American Council for Technology and Industry Advisory Council’s (ACT-IAC) Innovation Award for improving the Army’s data-driven operations.
“The Army Vantage program is the cornerstone of the Army’s ability to make data-driven decisions across the force” said Doug Philippone, Global Defense Lead at Palantir Technologies. “This partnership reinforces what industry and government can do at speed to solve hard problems.”
📺 Ross Gerber ATTACKS Palantir | Breakdown and More Footage 🔥[embedyt] https://www.youtube.com/watch?v=o3KnakJRjkI[/embedyt]
📈 Palantir Stock Technical Analysis
Both the long and short-term trends are negative. It is better to avoid buying stocks with negative trends. PLTR is part of the Software industry. There are 346 other stocks in this industry, PLTR did better than 40% of them. PLTR is currently trading near the lower end of its 52-week range, which is not a good sign considering that the S&P500 Index is trading near new 52 week highs at the moment.
There is a support zone ranging from 17.96 to 18.37. This zone is formed by a combination of multiple trend lines in multiple time frames. There is a resistance zone ranging from 18.58 to 19.06. This zone is formed by a combination of multiple trend lines and important moving averages in multiple time frames.
PLTR has a bad technical rating, but it does show a decent setup pattern. Prices have been consolidating lately and the volatility has been reduced. There is a support zone below the current price at 18.37, a Stop Loss order could be placed below this zone. We notice that large players showed an interest for PLTR in the last couple of days, which is a good sign.